SANES

10.734

+2.35%↑

BBVA

19.945

+2.97%↑

BNP

92.75

+3.14%↑

CABK

11.7

+2.23%↑

INGA

27.14

+2.61%↑

SANES

10.734

+2.35%↑

BBVA

19.945

+2.97%↑

BNP

92.75

+3.14%↑

CABK

11.7

+2.23%↑

INGA

27.14

+2.61%↑

SANES

10.734

+2.35%↑

BBVA

19.945

+2.97%↑

BNP

92.75

+3.14%↑

CABK

11.7

+2.23%↑

INGA

27.14

+2.61%↑

SANES

10.734

+2.35%↑

BBVA

19.945

+2.97%↑

BNP

92.75

+3.14%↑

CABK

11.7

+2.23%↑

INGA

27.14

+2.61%↑

SANES

10.734

+2.35%↑

BBVA

19.945

+2.97%↑

BNP

92.75

+3.14%↑

CABK

11.7

+2.23%↑

INGA

27.14

+2.61%↑

Home・Stock List・Sartorius Stedim Biotech.

Sartorius Stedim Biotech.

Open

SectorFinance

171.8 0.47

Buy Sell

Overview

Share price change

24h

Current

Min

170.7

Max

172.3

Key metrics
By Trading Economics
Income	41M 88M
Sales	-11M 762M
P/E Sector Avg	57.428 58.236
EPS	1.17
Profit margin	11.569
Employees	10,456
EBITDA	26M 225M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+36.5% upside

Dividends
By Dow Jones
Next Earnings	23 Jul 2026

Market Stats
By TradingEconomics
Market Cap	-2.7B 15B
Previous open	171.33
Previous close	171.8

News Sentiment

By Acuity

11%

89%

6 / 438 Finance

Sartorius Stedim Biotech. Chart

Past performance is not a reliable indicator of future results.

Related News

24 May 2026, 23:46 UTC

Market Talk

Pullback in Oil Prices Could Temper Inflation Expectations -- Market Talk

24 May 2026, 23:45 UTC

Market Talk

Gold, Silver Rise on Hopes for U.S.-Iran Deal -- Market Talk

24 May 2026, 23:42 UTC

Market Talk

Mineral Resources Bull More Positive Post Site Visit -- Market Talk

24 May 2026, 23:34 UTC

Market Talk

Oil Falls Amid Prospects for Reopening of Strait of Hormuz -- Market Talk

24 May 2026, 23:11 UTC

Market Talk

RBNZ Likely to Stand Pat But Watch for Dissent -- Market Talk

24 May 2026, 22:26 UTC

Acquisitions, Mergers, Takeovers

Beach Energy: La Bella 2 Will No Longer Be Drilled as Part of Equinox Campaign

24 May 2026, 22:25 UTC

Acquisitions, Mergers, Takeovers

Beach Energy: Implied Transaction Value of Around A$130 Million After Tax

24 May 2026, 22:25 UTC

Acquisitions, Mergers, Takeovers

Beach Energy: Royalty Payments Likely to Total Around A$140 Million Based on Resource Booking

24 May 2026, 22:24 UTC

Acquisitions, Mergers, Takeovers

Beach Energy to Get Production Royalty of A$3.75/GJ in Deal

24 May 2026, 22:24 UTC

Acquisitions, Mergers, Takeovers

Beach Energy to Get A$70 Million Cash Proceeds When Deal Completes

24 May 2026, 22:23 UTC

Acquisitions, Mergers, Takeovers

Beach Energy Says Deal Includes Artisan Natural-Gas Discovery

24 May 2026, 22:23 UTC

Acquisitions, Mergers, Takeovers

Beach Energy Sells 60% Operated Interest in VIC/L35 Block in Otway Basin

24 May 2026, 22:11 UTC

Market Talk

Oil Price Unlikely to Return to Pre-Conflict Levels This Year -- Market Talk

24 May 2026, 22:04 UTC

Market Talk

Oil Price Likely Lower, Equities Higher on Iran Deal Talks Progress -- Market Talk

23 May 2026, 08:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

23 May 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

22 May 2026, 21:10 UTC

Earnings

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22 May 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

22 May 2026, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

22 May 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

22 May 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22 May 2026, 19:47 UTC

Earnings

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22 May 2026, 19:17 UTC

Market Talk

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22 May 2026, 19:10 UTC

Market Talk

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22 May 2026, 18:54 UTC

Market Talk

Global Equities Roundup: Market Talk

22 May 2026, 18:54 UTC

Market Talk

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22 May 2026, 18:38 UTC

Market Talk

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22 May 2026, 18:35 UTC

Acquisitions, Mergers, Takeovers

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22 May 2026, 18:09 UTC

Market Talk

Centralized Crypto Lending Slows in 1Q -- Market Talk

22 May 2026, 17:58 UTC

Market Talk

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

Peer Comparison

Price change

Sartorius Stedim Biotech. Forecast

Price Target

By TipRanks

36.5% upside

12 Months Forecast

Average 233 EUR 36.5%

High 262 EUR

Low 210 EUR

Based on 8 Wall Street analysts offering 12 month price targets forSartorius Stedim Biotech. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Sartorius Stedim Biotech. - Dist in the past 3 months.

Sentiment

By Acuity

6 / 438 Finance

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.